Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but its aberrant activation is recognised as a driver of neuroinflammation. […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!